Latest News

An intensive two-day Yale Cancer Research symposium, dedicated to advancing cancer science through innovation and strengthening partnerships between Yale University and Historically Black Colleges and Universities (HBCUs), brought together researchers from multiple disciplines this week.

Yale Cancer Center faculty and trainees joined 22,000 cancer researchers from around the world to share the latest advances in cancer science and medicine earlier this week in Chicago for the 116th American Association for Cancer Research (AACR) annual meeting. Dr. Patricia LoRusso, Amy and Joseph Perella Professor of Medicine at Yale Cancer Center and AACR President for 2024-25, shared her global view on cancer. “Cancer is a global disease—it spares no continent, no country. And each patient that gets the disease deserves treatment.”

A new study from scientists at Yale School of Medicine has identified N-acetyltransferase 10 (NAT10), an enzyme highly expressed in brain metastasis, as a driver of brain metastasis. NAT10 primarily functions by adding acetyl groups to RNA molecules, regulating their function, stability or translation.

Researchers in the Nguyen Lab at Yale School of Medicine focus on understanding how lung cancer metastasizes to distant organs, including the brain, and how cancer cells that reach the brain become resistant to drug therapy.

Chen Liu, MD, PhD, Chair of Yale Pathology, welcomes public school students to the 2nd Annual Yale Pathology Day, where they explored careers in pathology.

The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

A new study from Yale Cancer Center scientists has identified the chromatin regulator WDR5 as a possible new drug target in triple negative breast cancer.